Detalles de la búsqueda
1.
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
Gynecol Oncol
; 187: 105-112, 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38759516
2.
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
Oncologist
; 28(3): 252-257, 2023 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36718018
3.
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
Gynecol Oncol
; 171: 141-150, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898292
4.
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Gynecol Oncol
; 177: 20-31, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37625235
5.
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Gynecol Oncol
; 165(1): 40-48, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35115180
6.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(5): 620-631, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33743851
7.
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Gynecol Oncol
; 161(2): 496-501, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33637348
8.
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
Gynecol Oncol
; 162(3): 661-666, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34243976
9.
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 21(7): 957-968, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32553118
10.
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
Gynecol Oncol
; 157(3): 578-584, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32265057
11.
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Gynecol Oncol
; 159(1): 72-78, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32771276
12.
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gynecol Oncol
; 157(2): 379-385, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32081463
13.
Second-line lenvatinib in patients with recurrent endometrial cancer.
Gynecol Oncol
; 156(3): 575-582, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31955859
14.
Clinical trial participation and aggressive care at the end of life in patients with ovarian cancer.
Int J Gynecol Cancer
; 30(2): 201-206, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31911533
15.
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study.
Int J Gynecol Cancer
; 30(5): 596-601, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32114513
16.
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
N Engl J Med
; 374(8): 738-48, 2016 Feb 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-26933849
17.
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gynecol Oncol
; 153(3): 541-548, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31005287
18.
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
J Natl Compr Canc Netw
; 17(8): 896-909, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31390583
19.
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
Lancet Oncol
; 19(8): 1126-1134, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30026002
20.
Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study.
Br J Cancer
; 118(2): 162-170, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29182608